Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Moberg Pharma ABMBGPF 49 Days Sales Outstanding is 134.77 as of Jun. 2026, which is 170% above its 10-year median of 49.90. GuruFocus rates MBGPF with a GF Score™ of 49/100 and a GF Value™ of $1.21 (Fairly Valued). Among 945 Drug Manufacturers companies, Moberg Pharma AB ranks worse than 88.78% on this metric.
Moberg Pharma AB (OTCPK:MBGPF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Moberg Pharma AB Days Sales Outstanding Related Terms
Moberg Pharma AB Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Moberg Pharma AB's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moberg Pharma AB Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Moberg Pharma AB's Days Sales Outstanding falls into.
Moberg Pharma AB Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 134.77 mean?
Moberg Pharma AB (MBGPF) has a Days Sales Outstanding of 134.77 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Moberg Pharma AB and its competitors. This is 170% above median its historical median of 49.90. Over the past decade, Moberg Pharma AB's Days Sales Outstanding has ranged from 6.18 to 5,395.23. According to the industry distribution chart, Moberg Pharma AB ranks #839 out of 945 companies in the Drug Manufacturers industry, placing it in the top 88.8%.
Is Moberg Pharma AB's Days Sales Outstanding too high?
Moberg Pharma AB's current Days Sales Outstanding of 134.77 is 170% above median its 10-year median of 49.90. Over the past 10 years, this metric has ranged from a low of 6.18 to a high of 5,395.23. The Drug Manufacturers industry median Days Sales Outstanding is 71.80. Moberg Pharma AB's value of 134.77 is 87.7% above this industry median. Based on the distribution chart, Moberg Pharma AB ranks #839 out of 945 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Moberg Pharma AB has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #839 out of 945 companies for Days Sales Outstanding. This places Moberg Pharma AB in the lower half of its industry. The industry median Days Sales Outstanding is 71.80. Moberg Pharma AB's value of 134.77 is 87.7% above this benchmark. Historically, Moberg Pharma AB's own Days Sales Outstanding has ranged from 6.18 to 5,395.23 over the past decade. While the company's 10-year median is 49.90 vs. the industry median of 71.80, Moberg Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.80, based on 945 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moberg Pharma AB's current Days Sales Outstanding of 134.77 is 87.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Moberg Pharma AB and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moberg Pharma AB's current Days Sales Outstanding is 134.77, which is 170% above median its own 10-year median of 49.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Moberg Pharma AB (MBGPF) is currently considered Fairly Valued. The stock's GF Value™ is $1.21, compared to a current price of $1.10 — trading 9.1% below its estimated fair value. The current Days Sales Outstanding is 134.77, which is 170% above median its 10-year median of 49.90 and 87.7% above the Drug Manufacturers industry median of 71.80. Moberg Pharma AB's overall GF Score™ is 49/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Moberg Pharma AB (MBGPF), the current Days Sales Outstanding is 134.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moberg Pharma AB (MBGPF) Overvalued in 2026?
Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued.
The current stock price of $1.10 is trading 9.1% below its estimated GF Value™ of $1.21.
GuruFocus considers Moberg Pharma AB to be Fairly Valued.
Key valuation signals for MBGPF:
Days Sales Outstanding: 134.77 (170% above median its 10-year median of 49.90)
GF Value™: $1.21 vs. price of $1.10 (9.1% below fair value)
Industry Position: 87.7% above the Drug Manufacturers median (#839 of 945)
No single metric tells the full story. See the MBGPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
49GF Score
Get the complete analysis for MBGPF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBGPF has been successfully added to your 
